OR WAIT 15 SECS
July 21, 2015.
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, states research and consulting firm GlobalData.
However, the company's report adds that the expansion, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be inhibited by the highly generic nature of the genital herpes treatment space.
GlobalData analyst Daian Cheng commented: “The low price of generic drugs not only will limit the sales of existing treatment, it also poses an entry barrier for new therapies. [We] predicts that the patient share of marketed antiviral drugs will further shift from branded to generic versions by 2023."
“Despite these barriers," Cheng continued, "the rise in the number of treated patients due to natural population increases in the US and five European countries will produce moderate market growth. This will be further aided by the launches of Agenus’ HerpV and Genocea’s GEN-003 during the forecast period.”
GlobalData expects HerpV to launch in the US in 2019 and GEN-003 in 2021, with both products launching in the 5EU one year after their US entries. As such, their largest impacts in the 5EU will occur after 2023.